213 related articles for article (PubMed ID: 24962105)
1. Low-dose maintenance gemcitabine-carboplatin chemotherapy could be an alternative to continuous standard chemotherapy for patients with metastatic urothelial carcinoma.
Mitsuzuka K; Yamashita S; Namiki S; Yamada S; Sato K; Saito H; Kaiho Y; Ito A; Nakagawa H; Arai Y
Int J Urol; 2014 Nov; 21(11):1114-9. PubMed ID: 24962105
[TBL] [Abstract][Full Text] [Related]
2. Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial.
García-Donas J; Font A; Pérez-Valderrama B; Virizuela JA; Climent MÁ; Hernando-Polo S; Arranz JÁ; Del Mar Llorente M; Lainez N; Villa-Guzmán JC; Mellado B; González Del Alba A; Castellano D; Gallardo E; Anido U; García Del Muro X; Domènech M; Puente J; Morales-Barrera R; Pérez-Gracia JL; Bellmunt J
Lancet Oncol; 2017 May; 18(5):672-681a. PubMed ID: 28389316
[TBL] [Abstract][Full Text] [Related]
3. Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II--results of EORTC study 30986.
De Santis M; Bellmunt J; Mead G; Kerst JM; Leahy M; Maroto P; Skoneczna I; Marreaud S; de Wit R; Sylvester R
J Clin Oncol; 2009 Nov; 27(33):5634-9. PubMed ID: 19786668
[TBL] [Abstract][Full Text] [Related]
4. Multicenter Phase 2 Trial of Gemcitabine, Carboplatin, and Sorafenib in Patients With Metastatic or Unresectable Transitional-Cell Carcinoma.
Hurwitz ME; Markowski P; Yao X; Deshpande H; Patel J; Mortazavi A; Donadio A; Stein MN; Kelly WK; Petrylak DP; Mehnert JM
Clin Genitourin Cancer; 2018 Dec; 16(6):437-444.e6. PubMed ID: 30177237
[TBL] [Abstract][Full Text] [Related]
5. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial.
Galsky MD; Arija JÁA; Bamias A; Davis ID; De Santis M; Kikuchi E; Garcia-Del-Muro X; De Giorgi U; Mencinger M; Izumi K; Panni S; Gumus M; Özgüroğlu M; Kalebasty AR; Park SH; Alekseev B; Schutz FA; Li JR; Ye D; Vogelzang NJ; Bernhard S; Tayama D; Mariathasan S; Mecke A; Thåström A; Grande E;
Lancet; 2020 May; 395(10236):1547-1557. PubMed ID: 32416780
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine plus split-dose cisplatin could be a promising alternative to gemcitabine plus carboplatin for cisplatin-unfit patients with advanced urothelial carcinoma.
Kim YR; Lee JL; You D; Jeong IG; Song C; Hong B; Hong JH; Ahn H
Cancer Chemother Pharmacol; 2015 Jul; 76(1):141-53. PubMed ID: 26001531
[TBL] [Abstract][Full Text] [Related]
7. Biweekly carboplatin/gemcitabine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: report of efficacy, quality of life and geriatric assessment.
Bamias A; Lainakis G; Kastritis E; Antoniou N; Alivizatos G; Koureas A; Chrisofos M; Skolarikos A; Karayiotis E; Dimopoulos MA
Oncology; 2007; 73(5-6):290-7. PubMed ID: 18477854
[TBL] [Abstract][Full Text] [Related]
8. Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group.
Linardou H; Aravantinos G; Efstathiou E; Kalofonos C; Anagnostopoulos A; Deliveliotis C; Bafaloukos D; Athanasios Dimopoulos M; Bamias A;
Urology; 2004 Sep; 64(3):479-84. PubMed ID: 15351574
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial.
Birtle A; Johnson M; Chester J; Jones R; Dolling D; Bryan RT; Harris C; Winterbottom A; Blacker A; Catto JWF; Chakraborti P; Donovan JL; Elliott PA; French A; Jagdev S; Jenkins B; Keeley FX; Kockelbergh R; Powles T; Wagstaff J; Wilson C; Todd R; Lewis R; Hall E
Lancet; 2020 Apr; 395(10232):1268-1277. PubMed ID: 32145825
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy consisting of gemcitabine, carboplatin, and docetaxel as an active treatment for advanced urothelial carcinoma.
Tsuruta H; Inoue T; Narita S; Horikawa Y; Saito M; Obara T; Numakura K; Maita S; Satoh S; Tsuchiya N; Habuchi T
Int J Clin Oncol; 2011 Oct; 16(5):533-8. PubMed ID: 21431341
[TBL] [Abstract][Full Text] [Related]
11. [Combination therapy consisting of gemcitabine, docetaxel and carboplatin as a second-line chemotherapy for patients with MVAC-treated metastatic urothelial carcinoma].
Inoue T; Obara T; Saito M; Kumazawa T; Narita S; Horikawa Y; Yuasa T; Tsuchiya N; Satoh S; Habuchi T
Hinyokika Kiyo; 2008 Sep; 54(9):581-5. PubMed ID: 18975570
[TBL] [Abstract][Full Text] [Related]
12. Sequential chemotherapy using gemcitabine + carboplatin followed by gemcitabine + carboplatin + docetaxel for advanced upper-tract urothelial cancer.
Yoneyama T; Imai A; Hatakeyama S; Hashimoto Y; Koie T; Ohyama C
Int J Clin Oncol; 2015 Dec; 20(6):1179-84. PubMed ID: 26007690
[TBL] [Abstract][Full Text] [Related]
13. Vinflunine-gemcitabine versus vinflunine-carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1).
De Santis M; Wiechno PJ; Bellmunt J; Lucas C; Su WC; Albiges L; Lin CC; Senkus-Konefka E; Flechon A; Mourey L; Necchi A; Loidl WC; Retz MM; Vaissière N; Culine S
Ann Oncol; 2016 Mar; 27(3):449-54. PubMed ID: 26673352
[TBL] [Abstract][Full Text] [Related]
14. [Gemcitabine and carboplatin chemotherapy in advanced transitional cell carcinoma in regard to patients with impaired renal function].
Helke C; May M; Hoschke B
Aktuelle Urol; 2006 Sep; 37(5):363-8. PubMed ID: 17004181
[TBL] [Abstract][Full Text] [Related]
15. Gemcitabine Plus Cisplatin Split
Izumi K; Iwamoto H; Yaegashi H; Shigehara K; Nohara T; Kadono Y; Mizokami A
In Vivo; 2019; 33(1):167-172. PubMed ID: 30587618
[TBL] [Abstract][Full Text] [Related]
16. Vinflunine/gemcitabine versus carboplatin/gemcitabine as first-line treatment in cisplatin-ineligible patients with advanced urothelial carcinoma: A randomised phase II trial (VINGEM).
Holmsten K; Jensen NV; Mouritsen LS; Jonsson E; Mellnert C; Agerbæk M; Nilsson C; Moe M; Carus A; Öfverholm E; Lahdenperä O; Brandberg Y; Johansson H; Hellström M; Maase HV; Pappot H; Ullén A
Eur J Cancer; 2020 Mar; 127():173-182. PubMed ID: 31648851
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer.
Balar AV; Apolo AB; Ostrovnaya I; Mironov S; Iasonos A; Trout A; Regazzi AM; Garcia-Grossman IR; Gallagher DJ; Milowsky MI; Bajorin DF
J Clin Oncol; 2013 Feb; 31(6):724-30. PubMed ID: 23341513
[TBL] [Abstract][Full Text] [Related]
18. Combination of gemcitabine and paclitaxel is a favorable option for patients with advanced or metastatic urothelial carcinoma previously treated with cisplatin-based chemotherapy.
Ikeda M; Matsumoto K; Tabata K; Minamida S; Fujita T; Satoh T; Iwamura M; Baba S
Jpn J Clin Oncol; 2011 Oct; 41(10):1214-20. PubMed ID: 21903707
[TBL] [Abstract][Full Text] [Related]
19. Our experience with 23 consecutive patients on gemcitabine/carboplatin chemotherapy for treatment of metastasized transitional cell carcinoma of the urothelium.
Hoschke B; May M; Seehafer M; Helke C
Int J Urol; 2004 Jul; 11(7):461-6. PubMed ID: 15242353
[TBL] [Abstract][Full Text] [Related]
20. Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract: an alternative therapy.
Nogué-Aliguer M; Carles J; Arrivi A; Juan O; Alonso L; Font A; Mellado B; Garrido P; Sáenz A;
Cancer; 2003 May; 97(9):2180-6. PubMed ID: 12712469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
